Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1626 1628 1642
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17906138 | TREATMENT OF EPILEPSY | Non-Final OA | Katholieke Universiteit Leuven |
| 18546633 | Treatment of Hypertension-Related and Vascular Diseases | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18833767 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18033724 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | MERCK PATENT GMBH |
| 18570520 | PROTEASE INHIBITORS AND METHODS OF USE | Non-Final OA | The Cleveland Clinic Foundation |
| 17783455 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY A PHYTOPATHOGENIC MICROORGANISM OF THE GENUS MACROPHOMINA SPP. | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18010695 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 17912272 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 19025976 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | Non-Final OA | Iambic Therapeutics, Inc. |
| 18357320 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Non-Final OA | Iambic Therapeutics, Inc. |
| 18178192 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18030390 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18564778 | METHODS OF TREATING BREAST CANCER | Non-Final OA | ASTRAZENECA AB |
| 18248068 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18037556 | METHOD FOR CARRYING OUT REACTION OF ISATIN COMPOUND AND CYCLOPROPENONE COMPOUND AT LOW CATALYTIC AMOUNT | Non-Final OA | SOOCHOW UNIVERSITY |
| 18042103 | ORGANIC COMPOUNDS | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18580944 | AGONISTS OF TYRO3 AS PROTECTION AGAINST PODOCYTE INJURY IN KIDNEY GLOMERULAR DISEASE | Non-Final OA | The Government of the United States of America as represented by the Department of Veterans Affairs |
| 18580822 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | Non-Final OA | FLORATEK PHARMA SA |
| 18011138 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | Non-Final OA | INVENTISBIO CO., LTD. |
| 18572480 | PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18572641 | COMPOSITION FOR WOUND RELIEF AND INHIBITING A PHD PROTEIN AND METHODS OF TREATMENT | Non-Final OA | Curapep LLC |
| 18289511 | NITAZOXANIDE IN THE TREATMENT OF SEPSIS | Non-Final OA | GENFIT |
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | Non-Final OA | MEDSHINE DISCOVERY INC. |
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 18563953 | METHOD FOR SYNTHESIZING 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | Non-Final OA | HOVIONE SCIENTIA LIMITED |
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | Non-Final OA | Cavion, Inc. |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | Final Rejection | Taiho Pharmaceutical Co., Ltd. |
| 18031371 | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | Final Rejection | Tisento Therapeutics Inc. |
| 18255218 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | ORION CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy